TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

DYANAVEL XR

AMPHETAMINE
Metabolic Approved 2015-10-19
2
Indications
--
Phase 3 Trials
10
Years on Market

Details

Status
Prescription
First Approved
2015-10-19
Routes
ORAL
Dosage Forms
SUSPENSION, EXTENDED RELEASE

DYANAVEL XR Approval History

Loading approval history...

What DYANAVEL XR Treats

1 indications

DYANAVEL XR is approved for 1 conditions since its original approval in 2015. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Attention Deficit Hyperactivity Disorder
Source: FDA Label

DYANAVEL XR Boxed Warning

ABUSE, MISUSE, AND ADDICTION DYANAVEL XR has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DYANAVEL XR, can result in overdose and death [see Overdosage (10) ] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing DYANAVEL XR, assess each patient’s risk for abuse, misuse, and addiction. Educa...

Drugs Similar to DYANAVEL XR

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ADDERALL XR 10
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity Disorder
ADDERALL XR 15
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity Disorder
ADDERALL XR 20
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity Disorder
ADDERALL XR 25
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity Disorder
ADDERALL XR 30
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity Disorder
ADDERALL XR 5
AMPHETAMINE ASPARTATE
1 shared
Takeda
Shared indications:
Attention Deficit Hyperactivity Disorder
ADZENYS XR-ODT
AMPHETAMINE
1 shared
NEOS THERAPS
Shared indications:
Attention Deficit Hyperactivity Disorder
AMPHETAMINE SULFATE
AMPHETAMINE SULFATE
1 shared
PRINSTON INC
Shared indications:
Attention Deficit Hyperactivity Disorder
APTENSIO XR
METHYLPHENIDATE HYDROCHLORIDE
1 shared
RHODES PHARMS
Shared indications:
Attention Deficit Hyperactivity Disorder
ARYNTA
LISDEXAMFETAMINE DIMESYLATE
1 shared
AZURITY
Shared indications:
Attention Deficit Hyperactivity Disorder
AZSTARYS
DEXMETHYLPHENIDATE HYDROCHLORIDE
1 shared
COMMAVE THERAP
Shared indications:
Attention Deficit Hyperactivity Disorder
CONCERTA
METHYLPHENIDATE HYDROCHLORIDE
1 shared
Johnson & Johnson
Shared indications:
Attention Deficit Hyperactivity Disorder
COTEMPLA XR-ODT
METHYLPHENIDATE
1 shared
NEOS THERAPS INC
Shared indications:
Attention Deficit Hyperactivity Disorder
DAYTRANA
METHYLPHENIDATE
1 shared
NOVEN PHARMS INC
Shared indications:
Attention Deficit Hyperactivity Disorder
DEXEDRINE SPANSULE
DEXTROAMPHETAMINE SULFATE
1 shared
IMPAX LABS INC
Shared indications:
Attention Deficit Hyperactivity Disorder
DEXTROAMPHETAMINE SULFATE
DEXTROAMPHETAMINE SULFATE
1 shared
SPECGX LLC
Shared indications:
Attention Deficit Hyperactivity Disorder
DYANAVEL XR 10
AMPHETAMINE
1 shared
TRIS PHARMA INC
Shared indications:
Attention Deficit Hyperactivity Disorder
DYANAVEL XR 15
AMPHETAMINE
1 shared
TRIS PHARMA INC
Shared indications:
Attention Deficit Hyperactivity Disorder
DYANAVEL XR 20
AMPHETAMINE
1 shared
TRIS PHARMA INC
Shared indications:
Attention Deficit Hyperactivity Disorder
DYANAVEL XR 5
AMPHETAMINE
1 shared
TRIS PHARMA INC
Shared indications:
Attention Deficit Hyperactivity Disorder
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DYANAVEL XR FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

DYANAVEL XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older [see Clinical Studies ]. Limitations of Use The use of DYANAVEL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions , Use in Specific Populations ]. DYANAVEL XR is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Dis...

⚠️ BOXED WARNING

WARNING: ABUSE, MISUSE, AND ADDICTION DYANAVEL XR has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including DYANAVEL XR, can result in overdose and death [see Overdosage (10) ] , and th...

DYANAVEL XR Patents & Exclusivity

Latest Patent: Sep 2036

Patents (7 active)

US11590228 Expires Sep 7, 2036
US8062667 Expires Mar 29, 2029
US8597684 Expires Mar 15, 2027
US10086087 Expires Mar 15, 2027
US8747902 Expires Mar 15, 2027
US8883217 Expires Mar 15, 2027
US9675703 Expires Mar 15, 2027
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.